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Highlights 
 Both GI.2 and GI.1b lagoviruses caused acute forms of rabbit haemorrhagic 
disease 
 Cross-protection was partial and not identical between the two viruses 
 Case fatality from GI.2 varied between individuals due to as yet unknown 
parameters 
 Case fatality from GI.1b was related to age with a pattern never described before 
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Abstract 
European rabbits (Oryctolagus cuniculus) are severely affected by rabbit haemorrhagic 
disease (RHD). Caused by a lagovirus, the disease leads to losses in the rabbit industry 
and has implications for wildlife conservation. Past RHD outbreaks have been caused 
by GI.1/RHDV genotype viruses. A new virus belonging to the GI.2/RHDV2/b 
genotype emerged in 2010, quickly spreading and replacing the former in several 
countries; however, limited data are available on its pathogenicity and epidemiological 
factors. The present work extends these issues and evaluates cross-protection between 
both genotypes. Ninety-four and 88 domestic rabbits were challenged with 
GI.2/RHDV2/b and GI.1b/RHDV variant isolates, respectively. Cross-protection was 
determined by a second challenge on survivors with the corresponding strain. Mortality 
by GI.2/RHDV2/b was highly variable due to unknown individual factors, whereas 
mortality by GI.1b/RHDV was associated with age. Mortality in rabbits < 4 weeks old 
was 84%, higher than previously reported. Cross-protection was not identical between 
the two viruses because the ratio of mortality rate ratios for the first and second 
challenges was 3.80±2.68 times higher for GI.2/RHDV2/b than it was for GI.1b/RHDV. 
Rabbit susceptibility to GI.2/RHDV2/b varied greatly and appeared to be modulated by 
the innate functionality of the immune response and/or its prompt activation by other 
pathogens. GI.1b/RHDV pathogenicity appeared to be associated with undetermined 
age-related factors. These results suggest that GI.2/RHDV2/b may interact with other 
pathogens at the population level but does not satisfactorily explain the GI.1b/RHDV 
virus’s quick replacement. 
Keywords: Lagovirus; Oryctolagus cuniculus; Rabbit haemorrhagic disease; RHD; 
RHDV; RHDV2/b 
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1. Introduction 
Rabbit haemorrhagic disease (RHD) is caused by caliciviruses of the species Lagovirus 
europaeus (GI genogroup), which mainly affect European rabbits (Oryctolagus 
cuniculus). Rabbit haemorrhagic disease is rapidly fatal, highly infectious and 
characterized by acute necrotising hepatitis. It provokes high mortality rates (> 90%) in 
adult rabbits, but young kits are generally naturally resistant to lethal infection. First 
described in China in 1984, RHD viruses have spread worldwide, and at present, the 
disease is considered endemic in many European countries, Australia and New Zealand, 
being a constant threat to domestic and wild rabbits (reviewed in Abrantes et al., 2012).  
Until recently, and following the new nomenclature proposed by Le Pendu et al. (2017), 
all RHD-viruses belonged to the GI.1 genotype. In 2010, however, a new virus causing 
RHD outbreaks in France was identified (Le Gall-Reculé et al., 2011). This new 
lagovirus, referred to as the RHDVb variant (Dalton et al., 2012) or RHDV2 (Le Gall-
Reculé et al., 2013), differs phylogenetically from other lagoviruses (Le Gall-Reculé et 
al., 2013), being included in the new genotype, GI.2 (Le Pendu et al., 2017). This new 
virus, GI.2/RHDV2/b (hereafter GI.2), causes lower average mortality than GI.1-
genotype viruses, although induced mortality in very young rabbits is higher than that 
caused by GI.1.  
GI.2 has since rapidly spread throughout other European countries, replacing the 
previously circulating viruses, particularly those belonging to the GI.1b/RHDV variant 
(hereafter GI.1b) (Le Gall-Reculé et al., 2013; Dalton et al., 2014; Calvete et al., 2014; 
Mahar et al., 2018), and is also present in Australia (Hall et al., 2015). This rapid 
widespread virus has again created a new threat to rabbit farming and a negative 
ecological impact on wild rabbit populations. 
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Despite GI.2’s current widespread distribution, limited data are available on its 
pathogenicity (Le Gall-Reculé et al., 2013) and the factors involved in it rapidly 
replacing the previously circulating GI.1b virus. To extend the current knowledge on 
these issues, the present work determined the cross-protection between GI.2 and GI.1b, 
comparing their pathogenicity across rabbit age. The main goal was to elucidate 
whether pathogenic and/or antigenic differences between both viruses could involve any 
selective advantage of GI.2 over GI.1b in the field. 
2. Material and methods 
2.1. Experimental infections 
Minimal disease level New Zealand White laboratory rabbits were provided by Granja 
San Bernardo (Tulebras, Spain). Neither the rabbits nor their parents were 
myxomatosis- or RHD-vaccinated.  
Given the lack of previous data, sample size calculation for comparing two proportions 
(based on Z-testing) was used to approximate the sample size needed to detect 
differences between mortality rates caused by the same virus at the first and second 
challenges (the second was performed on rabbits that survived the first challenge by the 
other virus). A rounded 40% mortality rate by GI.2 from the first challenge was 
assumed from data reported by Le Gall-Reculé et al. (2013) in selected commercial 
New Zealand domestic rabbits. A 90% mortality rate was assumed for GI.1b at the first 
challenge for rabbits older than 8 weeks. Sample size calculations were conservative to 
detect halving in mortality rates from the first to second challenges at 80% statistical 
power and a 0.1 two-tailed significance level.  
After estimating minimum sample sizes, rabbits were separated into experimental age 
batches based on provider availability and RHD susceptibility, particularly to the GI.1b 
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virus. To reduce within-batch correlations, members from the same litter or breeding 
cage were not allowed in the same experimental age batch. 
In total, 94 rabbits distributed in 8 age batches and 65 rabbits distributed in 6 age 
batches were first challenged with GI.2 and GI.1b viruses, respectively (Table 1). To 
ensure that enough rabbits survived to be challenged with GI.2, given the high mortality 
by GI.1b in rabbits older than 8 weeks, most of the animals that were first challenged 
with this virus (60 of 65) were younger. To reduce the number of rabbits used for 
ethical reasons, data from 4 batches of adult rabbits (13-14.7 weeks of age) that were 
first challenged with the same GI.1b isolate in preliminary assays with identical 
protocol (not previously published) were added to the dataset to represent adult rabbit 
mortality. 
Two virus inocula were used for challenges. GI.1b inoculum was prepared from an 
isolate obtained from a naturally RHD-dead wild rabbit (Oryctolagus cuniculus) 
collected in the Huerva River Valley in 2008 in Zaragoza province (Spain) (GenBank 
acc. numbers KY498582 and MH159721 for the VP60 capsid protein and the RdRp 
gene respectively). The virus was passaged twice in laboratory rabbits, and a 20% liver 
homogenate in PBS was prepared from the liver of a laboratory rabbit dead from acute 
RHD. The tissue suspension was centrifuged, and the supernatant was diluted 100-fold 
in PBS, yielding an oral viral suspension of 5x103.5 LD50/ml for adult rabbits which 
was used for experimental challenges. Viral suspension was titrated by the Reed and 
Muench method (Reed and Muench, 1938), infecting 5 rabbits per serial dilution (10-1 
to 10-6) of the supernatant (data not published). GI.2 inoculum (GenBank acc. numbers 
MG022138 and MH159722 for the VP60 capsid protein and the RdRp gene 
respectively) was prepared following the same procedure from a naturally RHD-dead 
wild rabbit collected in 2013 from an experimental enclosed wild rabbit population in 
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Zaragoza province. The first GI.2 viral detection in this experimental population 
occurred in 2011, which quickly replaced the previously circulating GI.1b virus 
(Calvete et al., 2014). Given the substantial genetic diversification reported during last 
years for lagoviruses, phylogenetic analyses of VP60 and RdRp gene sequences (Dalton 
et al., 2018) were used to confirm that both isolates were not recombinants, at least in 
the subgenomic promoter region most prone to recombination events (Lopes et al., 
2015). (Appendix A: Supplementary material). 
The GI.2 viral suspension was not titred; however, because livers from rabbits that died 
from RHD by either GI.2 or GI.1b contain similar viral amounts (Le Gall-Reculé et al., 
2013) and an identical protocol was used to prepare both viral suspensions, it is 
assumed that a similar viral dose was administered in both inoculums. 
Experimental infections were performed under negative pressure in BSL2 (CITA) 
experimental facilities with filtered air. Rabbits were reared in separated individual 
cages with free access to water and food (rabbit pellets provided by Granja San 
Bernardo). To avoid cross-contamination, each experimental batch was placed in a 
different negatively pressurized room. Before the first challenge (day 0), a blood sample 
from each rabbit was taken from the marginal ear vein to confirm seronegativity against 
RHD with a commercial indirect ELISA test primarily developed to detect anti-GI.1b Ig 
G antibodies (Ingezim Rabbit. INGENASA Lab., Madrid, Spain).  Each rabbit then 
received 0.2 ml of the appropriate viral suspension (GI.2 or GI.1b) orally.  
After the first challenge, rabbits were monitored for clinical changes and mortality at 
least 4 times daily for 35 days post-infection. During this period, a blood serum sample 
was obtained from each rabbit on the 7th, 21st and 35th days post-infection to monitor 
seroconversions using the same commercial indirect ELISA test. Additional samples of 
AC
CE
PT
ED
 M
AN
US
CR
IPT
7 
 
EDTA blood were obtained from each rabbit in the 3.4, 4.5 and 10.5-week-old batches 
infected with either GI.1b or GI.2 (and the 15.5-week-old batch infected with GI.2) on 
the 0, 7th, 21st and 35th days post-infection to monitor variations in the following 
haematological parameters: haematocrit value (HCT), red blood cell counts (RBC), 
haemoglobin concentration (HGB), mean corpuscular volume (MCV), mean 
corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration 
(MCHC) and differentiated neutrophil, eosinophil, basophil, lymphocyte, monocyte and 
platelet counts. Analyses were performed by Albéitar Veterinary Laboratory (Zaragoza, 
Spain) by flow cytometry (cytometer Sysmex XT-2000iV). Liver transaminase, alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations were also 
evaluated in the serum for the same days and age batches using an autoanalyzer 
GERNON (RAL®) following reference procedures from the International Federation of 
Clinical Chemistry and Laboratory Medicine (IFCC). 
To estimate cross-protection between both viruses on the 35th day post-infection, a 
second challenge was conducted on rabbits that survived the first, following identical 
protocol. Thus, rabbits initially surviving GI.1b were then infected with GI.2 and vice 
versa, except 8 rabbits that were euthanized on the 35th day post-infection for logistic 
reasons (Table 1). After the 2nd infection, rabbits were monitored for 35 days for clinical 
changes and mortality. During this period, a blood serum sample was obtained from 
each rabbit on the 7th, 21st and 35th days post-infection to draw seroconversion using the 
same commercial indirect ELISA test. Haematological parameters and transaminase 
concentrations were not monitored after the second challenge. 
Dead rabbits, as well as those that survived to the end of the experiment and were then 
humanely euthanized, were necropsied and examined for macroscopic lesions. Then, the 
spleen and liver weight ratios to body weight were estimated. Liver samples were 
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collected to detect RHD virus by duplex real-time PCR (duplex qPCR). In addition, 
tissue samples from the liver, spleen, kidneys, lung and small intestine were collected 
from 42 rabbits to compare histopathological findings among those that had died by 
GI.2 (n = 13) at first or second challenge, those dead by GI.1b (n = 16) at first or second 
challenge (including 3 animals < 4-weeks-old) and surviving rabbits (n = 13). Tissue 
samples were fixed in 10% buffered formalin and routinely processed and stained with 
haematoxylin-eosin for histological examination. 
In addition to experimentally infected animals, 11 4.5-week-old rabbits were used as 
controls. Three were euthanized after reception and used as controls for 
histopathological comparisons with young rabbits. The remaining 8 were maintained in 
conditions identical to the infected rabbits for 70 days. During this period, a serum 
sample from each rabbit was obtained on the 0, 7th, 21st, 35th, 42nd, 56th and 70th days as 
seroconversion and transaminase concentration negative controls. EDTA blood samples 
were obtained on the same days, simultaneously with the experimentally infected 
rabbits to control natural variations in haematological parameters across the survey. 
Finally, the control rabbits were euthanized, and their samples were used as controls for 
histopathological comparisons with the older rabbits. 
All animal experiments were performed in compliance with the provisions of Spanish 
national and European laws (Law 32/2007, modified 6/2013, and RD 53/2013) and 
approved by the CITA Ethical Committee for Animal Experimentation (protocol 2014-
18). 
2.2. Duplex real-time PCR (duplex qPCR) 
Given the recent emergence of GI.2 and that the goal of the background research 
projects was to study RHD epidemiology before and after the spread of GI.2, a duplex 
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qPCR procedure was developed to detect both GI.1b and the new GI.2 genotype virus in 
a single analysis. 
Total RNA was extracted from 25 mg of liver tissue using TRI REAGENT (Sigma 
LifeScience, Madrid, Spain) according to the manufacturer’s instructions. For duplex 
qPCR, first-strand cDNA was synthesized from 1 μg of RNA using the SuperScript III 
reverse transcriptase kit (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions with the specific primer, 5’-
CCAATTGTTACTGGCAGTGGT-3’, described by Moss et al. (2002). This primer is 
located at positions 1470–1490 in the VP60 gene. 
Primers and probes were designed based on conserved regions after aligning a 524-bp 
fragment of the VP60 gene (corresponding to nucleotides 871 - 1394 in the VP60 gene 
according to the GenBank acc. Numbers, KY498582 and KY498543, for GI.1b and 
GI.2, respectively) from GI.1b and GI.2 isolates taken from Spain, France, Portugal and 
Italy. Specific molecular beacon probes were used for each virus. Primers and molecular 
beacon probes were designed by Mycrosynth (Mycrosynth, Balgach, Switzerland). 
Duplex qPCR was performed using an ABI Prism 7500 platform (Applied Biosystem, 
Madrid, Spain). Amplification was performed in 10-μl volume reactions containing 5 μl 
of Premix Ex Taq (2x) master mix (Takara, Japan), 0.1 μl of Rox ref dye II, 0.2 and 0.4 
μM of each primer and probe, respectively, 3.1 μl of RNase- and DNase-free water 
(Applied Biosystems, Madrid, Spain), and 1 μl of cDNA (500 ng). Thermal cycling 
conditions included one cycle at 95°C for 30 s to activate Taq polymerase and 50 cycles 
of cDNA amplification (95°C for 5 s and 59°C for 34 s). All samples were amplified in 
duplicate in the same run. More extensive information on development, specificity and 
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efficiency of the duplex qPCR is available in the supplementary material with this 
article (Appendix A: Supplementary material). 
2.3. Statistical analyses 
2.3.1. Lesions and blood parameters 
Variations in spleen and liver weight ratios to body weight were explored by fitting 
linear regression models in which rabbit age at death (in weeks), group and time to 
death (in hours) were included as predictor variables in the initial model. Age was 
included due to its physiological linear inverse relationship with both ratios. For group 
variables, data were divided into five groups: rabbits that died by GI.2 or GI.1b at the 
first or second challenge and the control and euthanized-survivor rabbits. Control and 
euthanized rabbit data were mixed since they did not differ in preliminary analyses. For 
analytical purposes, time to death of this group was assumed to be zero. Backward 
stepwise selection was applied to obtain the final model. Variables were retained in the 
model if the F statistic p value was ≤ 0.1. 
Changes in blood parameters (haematological parameters and liver transaminases) of 
the rabbits that survived the first challenge were evaluated adjusting a repeated 
measures ANOVA model to data recorded at the 0, 7th, 21st and 35th days post-infection 
for each blood parameter. As predictors, a variable with the following three levels: 
infection with GI.2, infection with GI.1b and no infection (data from non-infected 
control rabbits) was included in addition to its interaction term with the within-effect 
factor (time). Because physiological variation in these parameters is associated with 
age, the 3.4- to 4.5-week-old and 10.5- to 15.5-week-old rabbits were analysed 
separately. Non-infected control rabbit data from days 0 to 35 and days 35 to 70 were 
used as the control values, respectively. 
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2.3.2. Mortality and cross-protection 
Cross-protection was evaluated by fitting a Poisson regression model to mortality data 
with log-link function, in which the virus, the challenge and their interaction were 
included as binomial predictor variables. To reduce the confounding effect of rabbit age, 
mortality data for rabbits < 8 weeks old infected with GI.1b at the first challenge were 
not included. 
Putative factors associated with mortality were explored by fitting a Poisson regression 
model, with log-link function, to mortality data from the rabbit subset sampled for 
haematological parameters. Sex, age batch (both as categorical variables) and 
haematological parameters measured at day 0 (or the 35th day for the second challenge) 
were included as predictor variables in the initial model. Backward stepwise selection 
was used, and variables were retained in the final model if the Wald statistic p value 
was ≤ 0.1. A separate Poisson model was fitted to each virus and challenge. For the 
second challenges, absorbance values of the indirect ELISA test on the 35th day after the 
first challenge were also included in the predictor variables set as a surrogate of 
antibody concentration against RHD viruses. 
2.3.3. Time to death 
Student’s t-test was used to compare mean time to death (in hours) between rabbits 
infected with GI.2 or GI.1b at the first challenge and to test differences between rabbits 
infected with the same virus at the first or second challenge. Homogeneity of variances 
was assessed to apply the correct t-test.  
Factors related to time to death were explored by fitting a linear regression model to 
time to death values recorded from the rabbit subset sampled for haematological 
parameters. Sex, age-batch (as categorical variables) and haematological parameters 
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measured at day 0 (or the 35th day for the second challenges) were included as predictor 
variables in the initial model. Backward stepwise selection was used, and variables were 
retained if the F statistic p value was ≤ 0.1. A separate regression model was fitted to 
each virus and challenge. For the second challenge, ELISA test absorbance values on 
the 35th day were also included as predictor variables. 
2.3.4. Duplex qPCR 
Non-parametric Spearman's correlation, a two-tailed difference between two 
proportions test and two-tailed Fisher´s exact probability test were used to explore 
associations within duplex qPCR results of surviving rabbits.  
3. Results 
3.1. Histopathology, seroconversion and blood parameters 
In all, 253 experimental infections, 182 at the first and 71 at the second challenges, were 
performed. All rabbits that died did so from acute forms of RHD, except for 2 10.5-
week-old rabbits that survived to the first challenge with GI.1b. These two animals 
developed a chronic form of the disease, with severe jaundice, anorexia and 
concomitant bacterial infections and were euthanized 10 days after the challenge. 
At necropsy, all RHD-dead rabbits showed typical and similar gross lesions, with 
minimal or moderate generalized congestion. Tracheal mucosal reddening, pulmonary 
multifocal haemorrhages and severe congestion were noted. Livers were brittle with a 
generalized marked lobular pattern, while the spleens were dark red, with occasional 
splenomegaly.  
As expected, the major histopathological lesions present in all 29 rabbits that died by 
RHD were acute hepatitis with minimal to moderate multifocal necrosis, inflammation, 
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hepatic cord dissociation, bile duct proliferation and lobular atrophy. Hyperaemia and 
thrombi were also present in the lungs, kidneys or spleen. Most animals showed spleen 
follicle depletion, haemorrhaging, tubulonephrosis and tubular necrosis in the kidneys. 
Less frequent lesions (n = 7) were found in the small intestines, with individual cell 
necrosis and Peyer’s patch depletion. Lesion occurrence was not associated with rabbit 
age, time of death, viral genotype or challenge (data not shown). Rabbits that survived 
both challenges show no clinical signs, and no gross or histopathological lesions were 
found. 
The final regression model fitted to the spleen weight to body weight ratio (R2 = 
73.50%; n = 112; F = 151.17; p < 0.001) showed that the spleen ratio was directly 
related to time to death (parameter ± SE: 0.001 ± 0.0001; t = 10.84; p < 0.001) but not 
with the virus. This relationship, corrected by the age effect, is shown in Fig. 1 and 
shows a similar distribution trend over time for rabbits dead from both GI.2 and GI.1b. 
No change in liver weight was associated with RHD. 
Positive seroconversion was detected in all rabbits after the first challenge, 
demonstrating that all surviving rabbits were successfully infected. High ELISA 
absorbances were recorded for all rabbits until the end of the assay (Fig. 2). Absorbance 
values were consistently lower for GI.2, probably due to the lower sensitivity of the 
commercial ELISA test for this genotype, as the test was initially developed to detect 
anti-GI.1b antibodies. 
Repeated measures ANOVA models fitted to blood parameter variations showed no 
significant differences (p > 0.5 in all cases) in changes along the assay among non-
infected control rabbits and survivors 3.4-4.5 weeks old first challenged with GI.2 or 
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GI.1b (n = 16 and 9, respectively) or those 10.5-15.5 weeks old infected with GI.2 (n = 
8).  
3.2. Mortality and cross-protection 
The overall mortality rates at first challenge were 0.43 (40/94) and 0.67 (59/88) among 
rabbits infected with GI.2 and GI.1b, respectively. By experimental batches (Fig. 3), 
mortality from GI.2 at the first challenge was highly variable, ranging from 0.75 (6/8) to 
0 (0/15), with no specific age-related pattern. Conversely, mortality by GI.1b exhibited 
a marked, but unexpected, age pattern. Typical for this viral genotype, mortality was as 
high as 0.93 (26/28) in rabbits ≥ 8 weeks old and as low as 0.34 (12/35) in rabbits 
between 4 and 8 weeks old. However, the mortality rate in younger rabbits (< 4 weeks) 
was 0.84 (21/25), notably higher than expected. 
Regarding second challenges, all rabbits were infected at ages over 8 weeks. Two 
animals (9.5 and 11 weeks old) were euthanized just after the second challenge with 
GI.1b because of accidental spinal cord injuries, and were excluded from the assay. 
Total mortality rates were 0.07 (2/27) and 0.61 (27/44) in rabbits infected with GI.2 and 
GI.1b, respectively. Therefore, mortality caused by GI.2 was 5.74 (CI 95%: 1.48-22.25) 
times higher at the first than the second challenge, in contrast to mortality caused by 
GI.1b, which had a mortality rate ratio of 1.51 (CI 95%: 1.17-1.95) for rabbits ≥ 8 
weeks old. 
The Poisson regression model (Pseudo-R2 = 7.91%; n = 193; Wald χ2 =52.35; p < 
0.001) confirmed that the mortality caused by GI.1b was 2.18±0.29 (±SE) times higher 
than that by GI.2 (z = 5.95; p < 0.001) and that the mortality at the second challenge was 
0.17±0.12 times the mortality at the first (z = -2.52; p = 0.012). Interestingly, the 
interaction term showed that the mortality rate between the first and second challenges 
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was 3.80±2.68 times higher for GI.2 than for GI.1b (z = 1.89; p = 0.058), thus 
confirming that the cross-protection was asymmetric, i.e. it was not identical between 
both viruses.  
Regarding mortality-associated factors, the Poisson model obtained for rabbits first 
challenged with GI.2 (Table 2), showed that it was directly correlated with MCH and 
lymphocyte count but inversely correlated with MCHC and monocyte count. However, 
some degree of collinearity between experimental batches and haematological 
parameters was detected (Table 3), especially because the 10.5-week-old rabbit batch 
had the highest mean monocyte count and the lowest mortality rate (0%). To evaluate 
the effect of collinearity on these results, the same model was re-fitted, adding the batch 
as a predictor variable. The new model fit the differences in mortality among batches, 
showing statistically significant differences between the 10.5-week-old rabbit batch and 
the remaining batches (p < 0.001 in all comparisons). However, this model also 
estimated similar and statistically significant mortality rate ratios for the four 
haematological parameters as in the first model (Table 2), confirming that the 
haematological parameter relationships with mortality were not confounded by batch 
collinearity.  
Conversely, the Poisson model fitted to mortality by GI.1b at the first challenge only 
retained the batch as a predictor variable (Pseudo-R2 = 8.38%; n = 34; Wald χ2 = 8.61; p 
= 0.013), mainly due to differences between mortality rates in the 3.4-week-old (highest 
mortality) and 4.5-week-old (lowest mortality) batches (mortality rates ratio ± SE: 3.27 
± 1.42; z = 2.72; p = 0.006). No collinearity between haematological parameters and 
batches was observed as a putative confounding factor. 
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For the second challenges, the model fitted to mortality by GI.2 only retained the 
monocyte count (Table 2), again indicating that the monocyte count was inversely 
correlated with mortality. For GI.1b, no predictor variable was retained in the final 
model. 
3.3. Time to death 
Time to death among rabbits first challenged with GI.2 showed no evidence that 
supported any pattern associated with rabbit age (Fig. 4), showing a mean time to death 
of 52.77 hours after infection (SD = 11.72; range 35.50-83.00). Data for rabbits that 
were first challenged with GI.1b, however, showed a clear age-related pattern, with a 
higher mean time to death in the youngest batches. Rabbits under 5 weeks old showed a 
mean time to death of 116.72 hours (SD = 14.71; range 78.00-145.00) compared to a 
mean time to death of 50.56 hours for older rabbits (SD = 27.89; range 33.00-177.00). 
The last value was similar to that of rabbits first challenged with GI.2 (Student´s t-test = 
0.21; df = 35.96; p = 0.829). 
At the second GI.2 challenge, only two rabbits died at 74.50 and 99.80 hours after 
infection (mean = 87.12; SD=17.85), whereas rabbits killed by GI.1b exhibited a mean 
time to death of 65.93 hours (SD = 39.10; range 31.00 – 229.50), slightly higher, but not 
significantly different from values estimated for rabbits older than 5 weeks first 
challenged with the same virus (Student´s t-test = -1.31; df = 55; p = 0.195). 
For factors associated with time to death, no model could be adjusted to data for the 
rabbits first challenged with GI.2 (n = 15). For rabbits first challenged with GI.1b, only 
the batch was retained because of the longer time to death in younger age classes (R2 = 
84.89%; n = 20; F = 47.77; p < 0.001). The model fitted to rabbits that were secondly 
challenged with GI.1b only retained ELISA absorbance values (R2 = 26%; n = 22; F = 
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7.02; p = 0.010), indicating a direct relationship between this variable and time to death 
(parameter ± SE: 62.05 ± 23.41; t = 2.65; p = 0.010). 
3.4. Duplex qPCR results 
For all rabbits that died from RHD, duplex qPCR of liver tissue confirmed the presence 
of the virus used in the last challenge, with mean Cq values (± SD) of 18.50 (± 2.78) 
and 17.12 (± 2.21) for rabbits that died from GI.2 and GI.1b respectively. Analysis 
detected no coexistence of both viruses in the same sample for any case.  
Rabbits euthanized after surviving both challenges (n = 42) were positive on the duplex 
qPCR in 30 cases (Table 4). The combined positivity rates for each virus (virus detected 
alone or in combination with another in the same sample) were directly correlated with 
rabbit age for GI.1b at the first challenge (Spearman r = 0.97; p = 0.005); however, this 
relationship was not evident for GI.2 or at the second challenge. The combined 
positivity rate for GI.2 was higher when this virus was used in the first challenge (0.65) 
than in the second (0.36) (two-tailed difference between proportions test p = 0.075); 
however, they were similar for GI.1b (0.52 vs 0.53; two-tailed difference between 
proportions test p = 0.955) (Table 4). Combined positivity rates for both viruses at the 
first challenge were not statistically significant (0.65 vs 0.52, respectively; two-tailed 
difference between proportions test p = 0.419), being similar to the positivity rate of 
GI.2 (4 from 8) for surviving rabbits that were only first challenged with this virus. 
Positivity for both viruses occurred simultaneously in 12 of the 30 positive rabbits. 
Positivity rates for both viruses were higher in rabbits first infected with GI.2 (0.41) 
than in those first infected with GI.1b (0.20), mainly because most GI.1b-positive 
rabbits at the second challenge were also GI.2-positive (7 from 9), although not 
significantly (two-tailed Fisher´s exact test probability = 0.335). Positivity to both 
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viruses in rabbits first challenged with GI.1b was more balanced and did not differ 
significantly (two-tailed Fisher´s exact test probability = 1). 
As expected, Cq values were higher in survivor rabbits than in RHD-dead rabbits. Mean 
Cq (± SD) values being 33.82 (± 4.90) and 33.48 (± 5.43) for GI.2 and GI.1b 
respectively. 
4. Discussion 
First reports conducted in France stated that GI.2 induces a more prolonged disease and 
a higher occurrence of subacute/chronic forms than GI.1 viruses (Le Gall-Reculé et al., 
2013). In the present study, however, both isolates caused acute forms of RHD, and the 
average time to death post-infection was analogous, except for rabbits younger than 8 
weeks infected with GI.1b. Clinical symptoms and lesions were also similar, including 
an increased spleen size, which depended on time to death post-infection but not on the 
virus type. Our results demonstrate that both viruses cause a similar disease, consistent 
with other surveys that reported the predominance of acute RHD forms caused by GI.2 
(Dalton et al., 2012; Capucci et al., 2017; Carvalho et al., 2017). 
After the first challenge, all surviving rabbits showed a clear seroconversion, 
confirming that all individuals were infected. Previous experimental challenges 
performed with GI.1b have shown that variations in haematological parameters occur a 
few hours after infection, with major changes peaking between 24 and 72 h post-
infection, whereas surviving rabbits quickly recover normal values, usually before the 
7th day (Ferreira et al., 2004; Ferreira et al., 2006a; Marques et al., 2012). Serum 
transaminase activity appears to follow a similar pattern (Marques et al., 2012), 
although Ferreira et al. (2004) reported persistently elevated AST and ALT values in 
young surviving rabbits through the 21st day post-infection. 
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In the present study, no marked deviations in blood parameters were observed compared 
with control rabbits from the 7th to 35th days post-infection, regardless of virus or rabbit 
age. This suggested that after the acute phase, the infection course was similar for both 
viral genotypes with no long-term changes; thus, even rabbits under 4 weeks old did not 
continue to undergo remarkable hepatic lesions.  
Young rabbits are innately resistant to fatal infection by GI.1b (Marcato et al., 1991; 
Shien et al 2000; Ferreira et al., 2004). Marques et al. (2014) demonstrated that this 
protection can be reversed by artificial immunosuppression, suggesting that the innate 
immune mechanisms of young rabbits cause this resistance. Young RHD-dead rabbits 
also developed an acute form of the disease because GI.1b pathogenicity in rabbit kits is 
linked to high viral replication levels (Matthaei et al., 2014). 
In our study, the GI.1b mortality pattern in young rabbits was unusual and implied an 
unplanned deviation from the initial experimental design, since the outstanding 
mortality rate registered for rabbits under 4 weeks old (21 of 25) has never been 
reported. These rabbits also developed an acute form of RHD but the mean time to 
death was considerably higher (double) than described in both adult and young rabbits 
(Marques et al., 2014; Matthaei et al., 2014). 
Genetic background of the rabbit strain used could be an underlying putative cause 
since variations in HGGA, SEC1 and FUT2 genes have been associated with genetic 
susceptibility to the GI.1 virus (Guillon et al., 2009; Nyström et al. 2011). Another 
cause could be increased virulence as an adaptation to persist in high density wild rabbit 
populations (Elsworth et al., 2014). When we isolated the GI.1b virus, neither changes 
in RHD epidemiology nor major variations in the dynamic population were noticed in 
the wild rabbit population where the virus was circulating. Nevertheless, it is probable 
AC
CE
PT
ED
 M
AN
US
CR
IPT
20 
 
that these changes were unnoticed because the rabbit population was at high density. 
This would imply that mean age at first infection was low, enhancing the role of kit 
protection by maternal antibodies and limiting RHD’s negative impact at population 
level (Calvete 2006).  
A third hypothesis could be immunosuppression induced by stress subsequent to early 
weaning, housing and management of the kits. However this hypothesis contrasts with 
the fact that no abnormal mortality pattern was observed in the batch of kits inoculated 
with GI.2, subjected to the same factors stress. 
The GI.1b isolate was obtained two years before the occurrence of the new GI.2 that 
infects young rabbits. Recombination plays an important role in generating diversity in 
lagoviruses (Lopes et al., 2015; 2017). Although the VP60 and RdRp gene sequences of 
our isolate corresponds to GI.1b genotype, full genomic analysis must be performed, 
and future studies are needed to identify the causes of these results. 
As expected, mortality from GI.2 at the first challenge was lower than mortality by 
GI.1b, but the GI.2 mortality pattern was unrelated to rabbit age. Le Gall-Reculé et al. 
(2013) reported that pathogenicity differed significantly among GI.2 isolates and within 
them, to a lesser extent. In the present survey, GI.2 mortality rates varied considerably 
among rabbit batches (from 0 to 75%), demonstrating highly variable pathogenicity 
within the same isolate despite using rabbits from a single genetic strain and origin. This 
suggests that future studies to project GI.2 pathogenicity should consider this variability 
and that the differences among isolates should be interpreted with caution when small-
scale assays are performed. 
The factors associated with this variability are unknown. Our results showed that over 
23% of the mortality rate variability caused by GI.2 at the first challenge was related to 
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variations in haematological parameters such as MCH, MCHC and lymphocyte and 
monocyte counts, whereas at the second challenge, 40% of the variability was 
associated with monocyte count. These haematological parameters are related to the 
three lines by which pluripotent bone marrow stem cells differentiate, the line of 
erythrocytes and blood platelets and the myeloid and lymphoid cell lines. Therefore, our 
results would indicate that individual innate differences in the immune system caused 
the susceptibility to developing a fatal disease after GI.2 infection. This result contrasts 
with that for GI.1b, for which only age was associated with mortality. This suggests that 
host-virus interaction mechanisms differ between both viruses and that GI.2 
pathogenicity may be more modulated by innate immunity than GI.1b, which is mainly 
conditioned by obscure age-related factors. 
An alternative hypothesis for this variable pathogenicity would be based on the small-
scale assay of Capucci et al. (2017). These authors observed that the replication of 
highly pathogenic RHDV was strongly inhibited in rabbits suffering from severe 
enteritis (likely caused by enteric bacterial infection), suggesting that the prompt 
activation of the innate immune system by other pathogens could indirectly limit viral 
replication. Following their hypothesis, and given that our rabbits were healthy and no 
clinical signs were observed in any rabbits, our results may indicate that undetected 
concomitant infections by non-pathogenic agents could have occurred in some rabbits, 
determining their fate after the viral challenge. The mean haematological parameter 
values, however, were within baseline ranges determined by the rabbit supplier (data 
unpublished). Therefore, this hypothesis would not be strongly supported, although it 
can not be completely rejected either. 
Cross-protection between both virus genotypes has been scarcely characterized. 
Mortality rates caused by GI.2 in rabbits vaccinated against GI.1b indicate limited 
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antibody roles in cross-protection (Le Gall-Reculé et al., 2011; Dalton et al., 2014). 
Moreover, in a small-scale assay, Le Gall-Reculé et al. (2013) showed that previous 
infection with GI.2 induced weak partial protection against GI.1b, whereas Peacock et 
al. (2017) confirmed that wild rabbits with naturally acquired anti-GI.1b antibodies can 
be infected by and die from GI.2.  
In the present study, ELISA absorbance values were uncorrelated with mortality, 
supporting a minor role of antibodies in cross-resistance. Only longer time to death in 
rabbits that were secondly challenged with GI.1b was associated with higher absorbance 
values, likely because humoral immunity delayed productive viral replication. However, 
given the characteristics and limitations of the ELISA, it is impossible elucidate if 
rabbits that survived the second challenge had effective contact with the second virus 
and the nature of the immune response (if any) to the second challenge, either as a 
primary or secondary response; therefore, its role in cross-protection remains unknown. 
Mortality rates caused by each virus were lower at the second challenge, confirming that 
partial, but asymmetric, cross-protection occurred. Strive et al. (2013) described a 
similar scenario where the non-pathogenic Australian rabbit calicivirus (RCV-A1) 
provided temporal and partial cross protection to GI.1c, unrelated to serum antibodies 
titres. These authors argued cellular immune mechanisms were the subjacent cause, 
since short-term elevation of non-specific innate immune mechanisms following the 
first infection may increase infectious disease resistance. This may be the reason for the 
asymmetric cross-protection observed in the present study. Given that host-virus 
interactions appear to differ between both viruses, and GI.2 pathogenicity may be 
modulated by innate immunity more than GI.1b, activation of innate immune 
mechanisms after the first challenge would yield a lower GI.2 pathogenicity at the 
second challenge.  
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Interestingly, this modulatory mechanism would imply that GI.2 interacts with other 
pathogens in both domestic and wild rabbits. Thus, other co-circulating microparasites 
(Myxoma viruses or other lagoviruses) could modulate the impact of RHD caused by 
GI.2 depending on outbreak timing or whether GI.2 was the first or second challenge 
for rabbits (Cox, 2001). Moreover, mortality caused by GI.1b at the second challenge 
was even higher than that caused by GI.2 at the first infection. This result contrasts with 
the effective replacement of GI.1b by the new viral genotype a few months after its 
spread (Le Gall-Reculé et al., 2013; Dalton et al., 2014; Calvete et al., 2014). Although 
GI.2’s ability to infect kits implies a viral epidemiological advantage, the limited cross-
protection and high mortality caused by GI.1b at the second challenge suggests that 
GI.1b viruses should have had greater probabilities to continue circulating in wild rabbit 
populations. However, interactions among lagoviruses, both at population and host 
levels are complex and poorly known (Strive et al., 2010; Strive et al., 2013). Therefore, 
because our results are a single estimate of cross-protection at a fixed time point (35 
days after first infection), they are limited, and their implications in RHD epidemiology 
should be interpreted with caution. 
Regarding duplex qPCR results in surviving rabbits, lagovirus RNA can be detected in 
convalescent rabbit tissues months after infection. The nature of lagoviral RNA 
persistence is unclear, and although this has led to the conclusion that persistent 
infections have been established, this RNA has not shown to be related to existing 
infective viruses, likely because the high antibody levels in the surviving animals 
originate immunocomplexes with viral particles (Shien et al., 2000; Forrester et al., 
2003; Gall et al., 2007; Strive et al., 2010). 
In the present study, viral RNA was detectable 10 weeks after infection at a similar rate 
(more than half the rabbits) for both viruses, but with some differences since GI.2 
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positivity rates showed no age-related pattern at the first challenge. The GI.2 positivity 
rates in rabbits that were secondly challenged were lower than those in the first 
challenge. This finding may suggest a more modulated GI.2 pathogenicity by a previous 
GI.1b infection, which may have lowered virulence or stimulated quicker GI.2 
clearance. 
All GI.1b-positive rabbits infected with this virus at the first challenge were younger 
than 8 weeks, and the positivity rate was directly correlated with age. These results 
agree with the hypothesis that young rabbits may be long-term GI.1b transmission 
vehicles (Ferreira et al., 2004), which is unlikely in older rabbits given their high 
mortality when infected with this viral genotype. GI.1b RNA was only detected in older 
rabbits when they were secondly challenged with this virus. In these rabbits, the 
positivity rate was similar than in young rabbits first infected with GI.1b, although the 
shorter time elapsed after the infection in older rabbits could have implied higher viral 
clearance. 
Finally, co-occurrence of both viruses in the same sample did not statistically differ 
from a random distribution, although the results may indicate that GI.1b RNA from the 
second challenges was detected at a higher probability if GI.2 RNA had been present. 
However, these results are weak and should be carefully interpreted. For example, 
because RNA from both viruses was not detected simultaneously in any rabbit dead 
from RHD in the second challenge (27 animals by GI.1b and 2 by GI.2), mortality after 
the second challenge may have only occurred in rabbits that did not carry the virus from 
the first challenge and, therefore, the proportion of viral RNA-positive surviving rabbits 
was lower than that estimated after the second challenge, especially for GI.2. However, 
for this interpretation, it should be assumed that duplex qPCR was sufficiently sensitive 
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to detect very low viral quantities in tissues from rabbits that died from acute RHD 
caused by another one (no inhibition interference), but this has not been evaluated. 
In conclusion, the present study demonstrates that the form of RHD caused by both 
viruses was similar, although the results showed that their host interactions differed 
markedly. An asymmetric partial cross-protection between both isolates was also 
determined, as were different mortality patterns: GI.2 was age-independent, whereas 
GI.1b was clearly modulated by age, although unexpectedly. Mortality caused by GI.2 
was highly variable and related to individual factors, although the mechanisms are 
unknown. The results obtained, especially those regarding cross-protection, do not 
satisfactorily explain the quick and effective replacement of GI.1b viruses by the new 
GI.2 in the wild; thus, more studies are necessary to elucidate the interactions among 
these lagoviruses. 
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FIGURE CAPTIONS 
Fig.1. Variation of spleen weight to body weight ratio corrected by age (partial residuals 
are presented) in relation to time to death (horizontal axis, in hours).  Black triangles: 
rabbits dead by GI.2 in first or second challenge; white circles: rabbits dead by GI.1b in 
first or second challenge; crosses: non-infected control and infected surviving-
euthanized rabbits. 
 
Fig.2. Mean (CI95%) of absorbance (OD) values measured with ELISA test for 
detection of serum antibodies against RHD viruses along the assay. Circles: non-
infected control rabbits; triangles: rabbits first challenged with GI.2; squares: rabbits 
first challenged with GI.1b. In horizontal axis days since the first challenge. Second 
challenge was performed at day 35. 
 
Fig. 3. Mortality rates and CI95% estimated for each experimental batch of rabbits after 
the oral infection with GI.2 or GI.1b viruses at first or second challenge. Vertical axe: 
mortality rate. Horizontal axe: age of rabbits (in weeks) in each experimental batch. 
 
Fig.4. Mean time to death (in hours) and CI95% of rabbits dead by RHD in each 
experimental batch after the oral infection with GI.2 or GI.1b viruses at first or second 
challenge. Vertical axe: time in hours. Horizontal axe: age of rabbits (in weeks) in each 
experimental batch. 
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Fig.4.  
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Table 1 
Challenged rabbits distribution across age-batches and virus isolates (RHD-dead 
rabbits/challenged rabbits). Second challenge with a virus was performed on rabbits 
surviving the first challenge by the other virus. 
 
First challenge  Second challenge 
Age (weeks) GI.2 GI.1b  Age (weeks) GI.1b GI.2 
3.4 6/15 14/15  8.4 5/9 0/1 
3.7  7/10  8.7  0/3 
4.4  4/10  9.4  0/6 
4.5 8/15 4/15  9.5 5/6 2/11 
5.1  4/10  10.1  0/6 
6.0 5/15   11.0 4/9  
6.1 4/6*      
10.5 0/15 3/5**  15.5 12/15  
11.5 9/14   16.5 1/5  
12.0 6/8*      
13.0  8/8***     
13.9  5/5***     
14.3  5/5***     
14.7  5/5***     
* Surviving rabbits were not secondly challenged with GI.1b. 
** The two surviving rabbits euthanized after developing chronic RHD form. 
*** Added batches 
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Table 2 
Poisson regression final models fitted to mortality data of rabbits infected with GI.2 at 
first and second challenges. 
 Mortality rates ratio (SE) z p 
First challenge model  
    
MCH (pg) 2.211 (0.465) 3.77 <0.001 
MCHC (g/dl) 0.435 (0.091) -3.99 <0.001 
Lymphocyte / mm3 1.001 (0.0003) 2.38 0.01 
Monocyte / mm3 0.997 (0.001) -2.61 0.009 
  
 Pseudo-R2 = 22.82%; n = 49; Wald χ2 =25.69; p < 0.001 
Second challenge model  
    
Monocyte / mm3 0.987 (0.004) -3.45 0.001 
  
 Pseudo-R2 = 40.22%; n = 25; Wald χ2 =11.93; p < 0.001 
 
Table 3 
Observed mean (SD) values for each experimental age-batch of haematological 
parameters retained in the final Poisson regression model fitted to mortality of rabbits 
infected at the first challenge with GI.2. 
Age of batch 3.4 weeks 4.5 weeks 10.5 weeks 15.5 weeks 
n 13 15 15 6 
MCHC (g/dl) 
(SD) 
29.05 
(3.41) 
29.54 
(2.44) 
31.08 
(0.57) 
31.26 
(0.47) 
MCH (pg) 
(SD) 
21.42 
(3.09) 
21.50 
(1.67) 
20.35 
(0.72) 
20.33 
(0.73) 
Lymphocyte / mm3 
(SD) 
1764.96 
(508.53) 
2115.79 
(443.86) 
4343.37 
(1229.99) 
5232.94 
(1216.93) 
Monocyte / mm3 
(SD) 
429.87 
(177.25) 
570.20 
(147.63) 
814.18 
(345.49) 
677.44 
(223.46) 
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Table 4 
Positive duplex qPCR results in liver tissues from rabbits surviving to both challenges 
(positivity rates in brackets). Combined results include positive results to one virus plus 
positive results to both viruses. 
 
Rabbits first challenged with GI.2 
Age* GI.2 Both** GI.1b GI.2 
combined 
GI.1b  
combined 
n 
3.4 2 (0.50) 0      (0) 0      (0) 2 (0.50) 0      (0) 4 
4.5 0      (0) 1      (1) 0      (0) 1      (1) 1      (1) 1 
6.0 1 (0.20) 4 (0.80) 0      (0) 5      (1) 4 (0.80) 5 
10.5 0      (0) 0      (0) 2 (0.67) 0      (0) 2 (0.67) 3 
11.5 1 (0.25) 2 (0.50) 0      (0) 3 (0.75) 2 (0.50) 4 
Total 4 (0.23) 7 (0.41) 2  (0.12) 11 (0.65) 9 (0.53) 17 
       
Rabbits first challenged with GI.1b 
Age* GI.1b Both** GI.2 GI.1b  
combined 
GI.2 
combined 
n 
3.4 0      (0) 0      (0) 1      (1) 0      (0) 1      (1) 1 
3.7 0      (0) 0      (0) 0      (0) 0      (0) 0      (0) 3 
4.4 2 (0.33) 0      (0) 0      (0) 2 (0.33) 0      (0) 6 
4.5 1 (0.11) 5 (0.55) 3 (0.33) 6 (0.67) 8 (0.89) 9 
5.1 5 (0.83) 0      (0) 0      (0) 5 (0.83) 0      (0) 6 
Total 8 (0.32) 5 (0.20) 4 (0.16) 13 (0.52) 9 (0.36) 25 
* Age at first challenge in weeks. Second challenge was carried out 5 weeks later. 
** Duplex qPCR positive to both viruses simultaneously 
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